Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

Pediatric Pulmonology

Volumn 44, Issue 2, 2009, Pages 134-141

  Krämer, Irene ^a   Schwabe, Astrid ^a   Lichtinghagen, Ralf ^c   Kamin, Wolfgang ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Compatibility; Cystic fibrosis; Dornase alfa; Multiple drug inhalation solution; Sodium metabisulfite; Tobramycin

Indexed keywords

DORNASE ALFA; EXCIPIENT; SODIUM CHLORIDE; SODIUM METABISULFITE; TOBRAMYCIN;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ASSAY; FLUORESCENCE; HUMAN; IMMUNOASSAY; LUNG INFECTION; MEDICAL NEBULIZER; OSMOLALITY; PH; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG COMBINATIONS; DRUG INCOMPATIBILITY; HUMANS; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL SOLUTIONS; PHYSICOCHEMICAL PROCESSES; TOBRAMYCIN;

EID: 59949099565     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20955     Document Type: Article

References (24)

1. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, Lannefors L. For the society task force on the use of nebulizers. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001;18:228-242.
2. Kamin W, Schwabe A, Kramer I. Inhalation solutions-which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006;5:205-213.
3. American Society of Health-System Pharmacists Inc. AHFS drug information 2006. Bethesda: ASHP; 2006.
4. Hutchinson TA, Shahan DR, editors. DRUGDEX® system. Vol. 130. Greenwood Village, CO: Micromedex; 2006.
5. Schwabe A, Krämer I, Lichtinghagen R, Kamin W. Physico- chemical compatibility of dornase alfa and tobramycin nebulizer solutions (poster). 10th Congress of the European association of hospital pharmacists, Lisbon, 16.-18.03.2005.
6. Krämer I, Schwabe A, Lichtinghagen R, Kamin W. Physico-chemical compatibility of nebulizable drug mixtures containing dornase alfa and ipatropium and/or albuterol. Pharmazie 2007; 62:760-766.
7. Fachinformation Pulmozyme® Hoffmann-La Roche AG, Gren-zach-Wyhlen; 06/2004.
8. Shire SJ. Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme® (Dornase Alpha)]. In: Pearlman R, Wang YJ, editors. Pharmaceutical Biotechnology. Vol. 9: formulation, characterization, and stability of protein drugs: case Histories. New York: Plenum Press; 1996. pp. 393-425.
9. Fachinformation TOBI® Chiron GmbH, München; 01/2003.
10. Fachinformation GERNEBCIN® 20 mg/40 mg/80 mg INFEC-TOPHARM Arzneimittel und Consilium GmbH, Heppenheim; 11/2005.
11. Lichtinghagen R. Determination of Pulmozyme® (dornase alpha) stability using a kinetic colorimetric DNase I activity assay. Eur J Pharm and Biopharm 2006;63:365-368.
12. Pharmacopoeia Europea. 5th Ed. Deutscher Apotheker Verlag, Stuttgart, Govi-Verlag-Pharmazeutischer Verlag, Eschborn, 2005.
13. Voigt R. Pharmazeutische Technologie: für Studium und Beruf. 9. vollständig überarbeitete Auflage. Stuttgart: Deutscher Apotheker Verlag; 2000.
14. EMEA Guideline on the pharmaceutical quality of inhalation and nasal products: http://www.emea.eu.int/pdfs/human/qwp/4931305en.pdf (16.05.2006).
15. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulizers for lung aerosol therapy. Lancet 1983;2:592-594.
16. McKenzie J, Gronberg S, Cruz Rivera M, Hoag J. Budesonide inhalation suspension can be nebulized with solutions containing albuterol sulphate (poster). Chest 2002;122:183S.
17. Smaldone GC, McKenzie J, Cruz Rivera M. Effect of nebulizer volume on drug delivery: budesonide inhalation suspension. Meeting of the American Thoracic Society, 2000 (personal communication).
18. Beasley R, Rafferty P, Holgate ST. Adverse reaction to the non- drug constituents of nebuliser solutions. Br J Clin Pharmacol 1988;25:283-287.
19. Elwood RK, Hogg JC, Paré PD. Airway response to osmolar challenge in asthma (abstract). Am Rev Respir Dis 1982;125:61.
20. Balmes JR, Fine JM, Christian D, Gordon T, Sheppard D. Acidity potentiates bronchoconstriction induced by hypoosmolar aerosols. Am Rev Respir Dis 1988;138:35-39.
21. Ratjen F. Aktuelle Aspekte zu Diagnostik und Therapie der Mukoviszidose. 1. Auflage. Bremen: UNI-MED Verlag AG; 2004.
22. Linz H, Nährlich L. Konsequenzen für die Physiotherapie. S.26-29. In: Mukoviszidose e.V. (Hrsg.) Leitfaden Inhalation bei Mukoviszidose. 1. Auflage. Mukoviszidose e.V., Bonn; 2005; pp. 26-29.
23. Borsje P, de Jongste JC, Mouton JW, Tiddens HAWM. Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. Pediatric Pulmonol 2000;30:368-376.
24. Van der Giessen LJ, Gosselink R, de Jongste JC, Hop WCJ, Tiddens HAWM. Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis. J Cyst Fibros 2005;4:S97.